Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group
Thomas Seufferlein, Waldemar Uhl, Marko Kornmann, Hana Algül, Helmut Friess, Alexander König, Michael Ghadimi, Eike Gallmeier, Detlef K. Bartsch, Manfred P. Lutz, Ralf Metzger, Kai Wille, B. Gerdes, Carl Christoph Schimanski, F Graupe, Volker Kunzmann, Ingo Klein, Michael Geißler, Ludger Staib, D. Waldschmidt, Christiane J. Bruns, Uwe A. Wittel, Stefan Fichtner‐Feigl, S Daum, Axel Hinke, L. Blomé, Andrea Tannapfel, Alexander Kleger, Adam Berger, Angelika Kestler, J.S. Schuhbaur, Lukas Perkhofer, Margaret A. Tempero, Anke Reinacher‐Schick, Thomas J. Ettrich
Topics & Concepts
MedicineGemcitabinePerioperativePancreatic cancerClinical endpointPopulationSurgeryInternal medicineChemotherapyRandomized controlled trialCancerEnvironmental healthPancreatic and Hepatic Oncology ResearchCancer, Stress, Anesthesia, and Immune ResponseCholangiocarcinoma and Gallbladder Cancer Studies